Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings

Research in Social and Administrative Pharmacy

Volumn 8, Issue 1, 2012, Pages 47-59

  Jain, Rahul ^a   Mullins, C Daniel ^b   Lee, Helen ^c   Wong, Winston ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c Pharmacy Management   (United States)

Author keywords

Diabetes; Differences in differences; Pattern of use

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG SUBSTITUTION; DRUG UTILIZATION; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK; STATISTICS;

AGED; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; DRUG UTILIZATION; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; THIAZOLIDINEDIONES;

EID: 84862951011     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2010.12.003     Document Type: Article

References (30)

1. Owens D.R. Thiazolidinediones: a pharmacological overview. Clin Drug Invest 2002, 22:485-505.
2. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004, 26(2):177-190.
3. Bell D.S. Type 2 diabetes mellitus: what is the optimal treatment regimen?. Am J Med 2004, 116(suppl 5A):23S-29S.
4. Yanagawa T., Araki A., Sasamoto K., Shirabe S., Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 2004, 53(3):353-357.
5. Henney J.E. Withdrawal of troglitazone and cisapride. JAMA 2000, 283(17):2228.
6. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106(6):679-684.
7. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
8. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26(11):2983-2989.
9. Hartung D.M., Touchette D.R., Bultemeier N.C., Haxby D.G. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case-control study. Pharmacotherapy 2005, 25(10):1329-1336.
10. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457-2471.
11. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298(10):1189-1195.
12. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298(10):1180-1188.
13. News F. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk. Available at: Accessed 01.12.09. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108966.htm.
14. FDA. FDA Adds boxed warning for heart-related risks to anti-diabetes drug Avandia. Available at: Accessed 01.12.09. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109026.htm.
15. American Heart Association. Risk factors and coronary heart disease. Available at: Accessed 12.12.08. http://www.americanheart.org/presenter.jhtml%3Fidentifier%3D4726.
16. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112(12):e154-e235.
17. Goodman L.A. Simultaneous confidence intervals for contrasts among multinomial populations. Ann Math Stat 1964, 35(2):716-725.
18. Goodman L.A. On simultaneous confidence intervals for multinomial proportions. Technometrics 1965, 7(2):247-254.
19. Ai C., Norton E.C. Interaction terms in logit and probit models. Econ Lett 2003, 80(1):123-129.
20. Mullahy J. Interaction effects and difference-in-difference estimation in loglinear models. NBER Technical Working Papers 1999, 254.
21. Norton E., Wang H., Ai C. Computing interaction effects and standard errors in logit and probit models. Stata J 2004, 4:103-116.
22. Greene W. Econometric Analysis 2003, Macmillan, New Jersey, Prentice Hall. 5th ed.
23. Starner C.I., Schafer J.A., Heaton A.H., Gleason P.P. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008, 14(6):523-531.
24. FDA. FDA public health advisory: worsening depression and suicidality in patients being treated with antidepressant. Available at: Accessed 01.12.2010. http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm.
25. FDA. FDA news: FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. Available at: Accessed 01.12.2010. http://www.fda.gov/bbs/topics/news/2004/NEW01124.html.
26. FDA FDA public health advisory: reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD) Available at:, Accessed 01.12.2010. http://www.fda.gov/cder/drug/advisory/mdd.htm.
27. Kurian B.T., Ray W.A., Arbogast P.G., Fuchs D.C., Dudley J.A., Cooper W.O. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 2007, 161:690-696.
28. Libby A.M., Brent D.A., Morrato E.H., Orton H.D., Allen R., Valuck R.J. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007, 164:884-891.
29. Libby A.M., Orton H., Valuck R.J. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009, 66:633-639.
30. Hennessy S., Bilker W.B., Weber A., Strom B.L. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf 2003, 12(2):103-111.